Suzanne Lentzsch

17.5k total citations · 2 hit papers
227 papers, 7.2k citations indexed

About

Suzanne Lentzsch is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Suzanne Lentzsch has authored 227 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Hematology, 136 papers in Molecular Biology and 77 papers in Oncology. Recurrent topics in Suzanne Lentzsch's work include Multiple Myeloma Research and Treatments (156 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (52 papers) and Protein Degradation and Inhibitors (51 papers). Suzanne Lentzsch is often cited by papers focused on Multiple Myeloma Research and Treatments (156 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (52 papers) and Protein Degradation and Inhibitors (51 papers). Suzanne Lentzsch collaborates with scholars based in United States, Germany and Canada. Suzanne Lentzsch's co-authors include Markus Y. Mapara, Teru Hideshima, Paul G. Richardson, Kenneth C. Anderson, Faith E. Davies, Klaus Podar, Boris K. Lin, Dharminder Chauhan, Noopur Raje and Brian G.M. Durie and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Suzanne Lentzsch

209 papers receiving 7.1k citations

Hit Papers

Thalidomide and immunomodulatory derivatives augment natu... 2001 2026 2009 2017 2001 2013 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    2001 740 citations Suzanne Lentzsch et al. Blood profile →
  2. IMWG consensus on risk stratification in multiple myeloma
    2013 413 citations Suzanne Lentzsch et al. profile →

Peers

Suzanne Lentzsch
Jonathan L. Kaufman United States
Natalie S. Callander United States
Melissa Alsina United States
Henk M. Lokhorst Netherlands
Rubén Niesvizky United States
Peter M. Voorhees United States
Torben Plesner Denmark
Hitoshi Kiyoi Japan
Shmuel Yaccoby United States
Bruno Paiva Spain
Jonathan L. Kaufman United States
Suzanne Lentzsch
Citations per year, relative to Suzanne Lentzsch Suzanne Lentzsch (= 1×) peers Jonathan L. Kaufman

Countries citing papers authored by Suzanne Lentzsch

Since Specialization
Citations

This map shows the geographic impact of Suzanne Lentzsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Lentzsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Lentzsch more than expected).

Fields of papers citing papers by Suzanne Lentzsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Lentzsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Lentzsch. The network helps show where Suzanne Lentzsch may publish in the future.

Co-authorship network of co-authors of Suzanne Lentzsch

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Lentzsch. A scholar is included among the top collaborators of Suzanne Lentzsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Lentzsch. Suzanne Lentzsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Basset, Marco, Mario Nuvolone, Andrea Foli, et al.. (2025). Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study. Blood Advances. 9(9). 2221–2225.
2.
Katodritou, Eirini, Evangelos Terpos, Suzanne Lentzsch, & Shaji Kumar. (2025). Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management. American Journal of Hematology. 101(4). 664–668. 1 indexed citations
3.
Li, Shirong, Huihui Ma, Rajshekhar Chakraborty, et al.. (2025). GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism. PubMed. 2(3). 100130–100130.
4.
Bhutani, Divaya, Yusha Liu, Rajshekhar Chakraborty, et al.. (2024). Translocation (11;14) is a common cytogenetic abnormality in clonal plasma cells in monoclonal immunoglobulin deposition disease. British Journal of Haematology. 205(5). 1860–1865.
5.
Shah, Veer, et al.. (2024). The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. Blood Advances. 8(13). 3464–3467.
6.
Fu, Jing, Shirong Li, Huihui Ma, et al.. (2023). The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease. Nature Communications. 14(1). 4271–4271. 9 indexed citations
7.
Gertz, Morie A., Rafat Abonour, Sarah N. Gibbs, et al.. (2023). Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis. ClinicoEconomics and Outcomes Research. Volume 15. 673–680.
8.
Joffe, Maureen, Moosa Patel, Codruța Chiuzan, et al.. (2022). Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men. Cancer Epidemiology Biomarkers & Prevention. 31(12). 2192–2198. 7 indexed citations
9.
10.
Bäcker, Henrik C., et al.. (2021). Flexor tenosynovectomy in carpal tunnel syndrome as a screening tool for early diagnosis of amyloidosis. Irish Journal of Medical Science (1971 -). 191(5). 2427–2430. 5 indexed citations
11.
Lentzsch, Suzanne, Raymond L. Comenzo, Jeffrey A. Zonder, et al.. (2020). Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. Journal of Clinical Oncology. 38(13). 1455–1462. 35 indexed citations
12.
Cooper, Dennis, Deepu Madduri, Suzanne Lentzsch, et al.. (2019). Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 3176–3176. 31 indexed citations
13.
Bhutani, Divaya, Siyang Leng, Andrew Eisenberger, et al.. (2018). Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101. Blood. 132(Supplement 1). 958–958. 11 indexed citations
14.
Fu, Jing, Huihui Ma, Xiaoming Xu, et al.. (2018). IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation. Blood Advances. 2(5). 492–504. 18 indexed citations
15.
16.
White, Darrell, Nizar J. Bahlis, Christopher P. Venner, et al.. (2017). A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 130. 1861–1861. 4 indexed citations
17.
18.
19.
Li, Shirong, Jing Fu, Caisheng Lu, et al.. (2016). Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma. Molecular Cancer Therapeutics. 15(4). 711–719. 20 indexed citations
20.
Feng, Rentian, Shirong Li, Caisheng Lu, et al.. (2011). Targeting the Microtubular Network as a New Antimyeloma Strategy. Molecular Cancer Therapeutics. 10(10). 1886–1896. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan L. Kaufman Breakdown of academic impact, for papers by Natalie S. Callander Breakdown of academic impact, for papers by Melissa Alsina Breakdown of academic impact, for papers by Henk M. Lokhorst Breakdown of academic impact, for papers by Rubén Niesvizky Breakdown of academic impact, for papers by Peter M. Voorhees Breakdown of academic impact, for papers by Torben Plesner Breakdown of academic impact, for papers by Hitoshi Kiyoi Breakdown of academic impact, for papers by Shmuel Yaccoby Breakdown of academic impact, for papers by Bruno Paiva
Rankless by CCL
2026